Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
five-component acellular pertussis vaccine
- Development stage
- Approved
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The five-component acellular pertussis vaccine is a protein subunit vaccine developed by Connaught Laboratories (now Sanofi Pasteur) for the prevention of pertussis (whooping cough) caused by *Bordetella pertussis*. It contains five highly purified antigenic components: glutaraldehyde-inactivated pertussis toxin (pertussis toxoid), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae types 2 and 3 (FIM2/3). This vaccine was developed as a safer alternative to whole-cell pertussis vaccines, demonstrating approximately 85.2% efficacy in clinical trials with a significantly lower incidence of adverse events such as fever and local reactions. It is typically administered as the pertussis component of combination vaccines including DTaP (e.g., Daptacel) and Tdap (e.g., Adacel), often adsorbed to an aluminum-based adjuvant to enhance the immune response.
- Brand names
- DaptacelAdacelPentacel
- Other names
- 5-component aPConnaught acellular pertussis vaccineacellular pertussis vaccine, five-component
02
Targets
FHA (Filamentous hemagglutinin)Fimbrial antigen type 3PRN (Pertactin)Fim2 (Bordetella pertussis fimbrial protein 2)Fim3 (Bordetella pertussis fimbrial protein 3)
Beyond the preview
Go deeper on five-component acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on five-component acellular pertussis vaccine.